Regeneron Pharmaceuticals (REGN) P/E ratio

P/E ratio today
21.2×

Regeneron Pharmaceuticals (REGN) trades at 21.2× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 18.6×. That is 0.2% higher than the 18.6× of fiscal 2024. Figures as of 18 Nov 2026, 11:09 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/E ratio today
21.2×
P/E ratio, fiscal 2025
18.6×
Change on fiscal 2024
+0.2%
Highest on record
137.7×fiscal 2014
Lowest on record
8.8×fiscal 2021
Fiscal years on record
142012–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Regeneron Pharmaceuticals P/E ratio, in more detail

Today's figure is 13.8% above the fiscal 2025 year-end.

Across the 14 fiscal year-ends on record (2012–2025), the highest was 137.7× in fiscal 2014 and the lowest 8.8× in fiscal 2021. Today's P/E ratio is higher than at 50% of the 14 fiscal year-ends on record; their median is 22.8×.

History · 14 fiscal years

P/E ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Regeneron Pharmaceuticals P/E ratio, year by year

Regeneron Pharmaceuticals (REGN) P/E ratio by fiscal year
Fiscal yearP/E ratioChangeYear endedShare price at year-endDiluted EPS
Today21.2×—$957.76—
202518.6× 0.2% up$771.87$41.48
202418.6× 26.4% down$712.33$38.34
202325.3× 33.8% up$878.29$34.77
202218.9× 115.1% up$721.49$38.22
20218.8× 44.6% down$631.52$71.97
202015.8× 22.2% down$483.11$30.52
201920.3× 15.9% up$375.48$18.46
201817.5× 51.8% down$373.50$21.29
201736.4× 23.7% down$375.96$10.34
201647.7× 51.5% down$367.09$7.70
201598.3× 28.6% down$542.87$5.52
2014137.7× 86.1% up$410.25$2.98
201374.0× 191.9% up$275.24$3.72
201225.3×—$171.07$6.75
2011——$55.43-$2.45
2010——$32.83-$1.26
2009——$24.18—
2008——$18.36—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.

How to read it

It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.

P/E ratio at health care companies of similar size

P/E ratio of Regeneron Pharmaceuticals and comparable companies
CompanyP/E ratio
CVS Health CVS10.0×
HCA Healthcare HCA16.6×
GSK GSK17.2×
Regeneron Pharmaceuticals REGN21.2×
Elevance Health ELV18.4×

Price over the last twelve months' earnings per share, as the market data feed reports it.

More on REGN

Regeneron Pharmaceuticals, figure by figure

Regeneron Pharmaceuticals (REGN) overview: price, valuation and scorecardAll health care companies by market value

Regeneron Pharmaceuticals P/E ratio: questions and answers

What is Regeneron Pharmaceuticals's P/E ratio?

Regeneron Pharmaceuticals (REGN) trades at 21.2× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 18.6×. That is 0.2% higher than the 18.6× of fiscal 2024.

Is Regeneron Pharmaceuticals's P/E ratio high or low compared with its own history?

Today's P/E ratio is higher than at 50% of the 14 fiscal year-ends on record; their median is 22.8×.

What are the highest and lowest P/E ratio figures on record for Regeneron Pharmaceuticals?

Across the 14 fiscal year-ends on record (2012–2025), the highest was 137.7× in fiscal 2014 and the lowest 8.8× in fiscal 2021.

How is Regeneron Pharmaceuticals's P/E ratio calculated?

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E. For Regeneron Pharmaceuticals it is on record here for 14 fiscal years, 2012 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Regeneron Pharmaceuticals (REGN) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/REGN/pe-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.